A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)

"Mesenchymal tumor" or "decidual-like reaction"? (1/85)

For more than 40 yr, an unusual urinary bladder lesion has been known to occur in certain strains of mice, but no consensus has been obtained regarding its etiology, pathogenesis, biology, or classification. The lesion was first assumed to be epithelial and non-neoplastic, then it was called a smooth muscle cell tumor or leiomyosarcoma because of ultrastructural characteristics for smooth muscle cells. Later, the nonspecific term "mesenchymal tumor" was introduced due to histomorphologic differences from all smooth muscle tumors known. Recently, a proposal was made to name it "decidual-like reaction" because of the histomorphologic similarity to the rare spontaneous decidual reaction in the uterus of aging mice. Both lesions are characterized by spindle and large pleomorphic epithelioid cells with large bizarre nuclei; these characteristics mimic anaplasia of malignant tumors and led pathologists to assume a neoplastic nature. The decidual hypothesis is supported by the regular presence of nuclear progesterone receptors, the occasional occurrence of eosinophilic cytoplasmic granules, the rare finding of cells morphologically resembling granulated metrial gland cells (all also observed in the uterine decidual reaction), and the reproducibility through long-term feeding of combinations of estrogens and progestogens. It appears that the new decidual hypothesis can explain many detailed facets of the lesion, with the exception of the reported smooth muscle cell characteristics. The controversy of "mesenchymal tumor versus decidual-like reaction" should be resolved soon, not only as a scientific issue, but also because of consequences for risk assessment.  (+info)

Retinol esterification activity contributes to retinol transport in stellate cells. (2/85)

The mechanisms of retinol transport and accumulation in hepatic stellate cells (HSC) remain to be elucidated. Our previous studies suggested that retinol esterification activity, particularly lecithin:retinol acyltransferase (LRAT) activity, in liver retinoid metabolism is important to elucidate the relationship between retinol uptake by HSC and the esterification of retinol. In the present study, using a human HSC-like cell line, LI90, we demonstrated that retinol esterification activity of LI90 cells is similar to that of primary cultures of rat HSC and higher than that of a human hepatoma cell line. Further, since progesterone or diphospho-lauroyl-phosphatidylcholine increased retinol esterification activity of LI90 cells, it is likely that LRAT contributes to retinol esterification in LI90. We examined retinol esterification in LI90 cells and clearance of retinol from culture medium. The percentages of both retinol and esterified retinol in LI90 cells increased in a manner dependent on retinol concentration in medium, whereas that of retinol in medium decreased. The percentages of esterified and unesterified retinol in LI90 cells and of retinol in medium were linearly dependent on the logarithm of the initial concentration of retinol in the medium. These results suggest that retinol esterification activity contributes to retinol uptake by HSC and maintenance of non-toxic retinol levels in plasma.  (+info)

Oesophageal mesenchymal tumours: clinicopathological features and absence of Epstein-Barr virus. (3/85)

BACKGROUND: Recent studies have suggested that the Epstein-Barr virus (EBV) is associated with smooth muscle tumours (leiomyoma and leiomyosarcoma) in patients with human immunodeficiency virus and in organ transplant recipients. Leiomyoma is the most common mensenchymal tumour found in the oesophagus. AIM: To report a single institution experience on oesophageal mesenchymal tumours and to determine whether EBV is associated with these tumours. METHODS: 40 sporadic oesophageal mesenchymal tumours were studied and their diagnosis confirmed on pathological review and immunohistochemical studies. Formalin fixed, paraffin was embedded tissues from these tumours were analysed for EBV using in situ hybridisation for two messenger RNA (mRNA) probes, EBER and BamH1 W. RESULTS: The oesophageal mesenchymal tumours comprised 36 leiomyomas, two undifferentiated stromal tumours, and two gastrointestinal autonomic nerve tumours (GANTs). Median age of the patients with leiomyoma (26 men, 10 women) was 62 years (range 30 to 85) and 81% of them had an asymptomatic lesion. The median longitudinal size was 1.2 cm. Multiple leiomyomas were seen in 11% of the patients and calcification was noted in one tumour. Coexisting squamous cell carcinoma was found in one third of cases. The stromal tumours were small, asymptomatic, and located in the lower third of the oesophagus, while the GANTs were large, symptomatic, and found in the upper third of the oesophagus. EBV mRNAs were not detected in all these tumours. CONCLUSIONS: The clinicopathological features of oesophageal leiomyoma, undifferentiated stromal tumour, and GANT were different. Some oesophageal leiomyomas were associated with oesophageal squamous cell carcinomas. EBV is not associated with sporadic oesophageal mesenchymal tumours.  (+info)

Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. (4/85)

OBJECTIVE: The study was designed to evaluate the clinical, endocrinological and radiological parameters used to investigate adrenal incidentalomas and select patients for surgery. DESIGN AND METHODS: An analysis of 88 consecutive patients with adrenal incidentaloma selected for surgery and investigated in a single clinical center was performed. RESULTS: Mean (+/-s.d.) age of the patients was 53+/-14 years. Fourteen (16%) of the adrenal incidentalomas were malignant tumors (2 adrenocortical carcinomas, 3 metastases, 4 adenocarcinomas, 4 sarcomas and 1 mesenchymoma), 10 (11%) were pheochromocytomas, 32 (36%) were non-secretory benign adrenal adenomas and the remaining were benign adrenal (n = 8; 9%) or extra-adrenal (n = 24; 27%) masses. Endocrinological investigations revealed 1 Conn adenoma, 4 tumors responsible for Cushing's syndrome or silent hypercortisolism and 1 androgen secreting tumor. Abnormalities of endocrine evaluations were observed in the 2 malignant adrenocortical carcinomas. Elevated 24-h urinary metanephrine levels were observed in the 9 pheochromocytomas tested. Complications of surgery occurred in 14% of the cases. Regardless of the endocrine status, parameters associated with malignant tumors were: older age (mean age of patients harboring malignant tumors vs patients with benign incidentalomas: 62+/-17 years vs 52+/-13 years, P = 0.005), weight loss (39% vs 7%, P = 0. 005), and mass diameter greater than 60mm (69% vs 15%, P < 0.001). By multiple logistic regression analysis malignant tumors were associated with increased age, diameter greater than 60mm and bilateral masses. CONCLUSION: This study points to a high rate of pheochromocytomas and malignant tumors in patients selected for surgery. This high rate differs from some previous reports and might be explained by the criteria used to select patients for surgery. Among these two groups of tumors, careful systematic endocrinological investigations allow the detection of altered secretion in the vast majority - if not all - malignant tumors of adrenal origin and pheochromocytomas. Only 5% of the incidentalomas below 30 mm selected for surgery in this study were malignant, in keeping with the use of this criteria as an important parameter to select patients with normal hormonal investigations for careful follow-up.  (+info)

Cartilage and bone containing benign mesenchymoma of the thigh and popliteal fossa. (5/85)

We report a case of a large cartilage and bone containing mesenchymoma of the thigh and popliteal fossa in a 56-year-old man. Mesenchymomas are rare tumors with a histologically benign pattern. They may be associated with morbidity as a result of local infiltrative growth.  (+info)

Gastrointestinal stromal tumors of the small intestine that expressed c-kit protein. (6/85)

We report two patients with gastrointestinal stromal tumors (GISTs) of the small intestine that expressed c-kit protein (CD117). One was a 68-year-old woman with epigastralgia and vomiting. A submucosal tumor of the upper jejunum was detected, and partial resection was carried out. The histology revealed a GIST negative for CD34 but positive for CD117. The other was a 42-year-old woman with progressive anemia, melena and lower abdominal pain. Intussusception was detected, and a partial resection was carried out. A submucosal tumor of the lower jejunum was noted. The histology revealed a GIST positive for both CD34 and CD117.  (+info)

The histopathological differential diagnosis of gastrointestinal stromal tumours. (7/85)

Gastrointestinal stromal tumours (GISTs), initially presumed to be of "true" smooth muscle origin, encompass a heterogeneous, and as yet incompletely understood, group of mesenchymal tumours with respect to their origin, cellular differentiation, and prognosis. Cellular morphology ranges from predominantly spindle shaped to epithelioid in character, whereas differentiation pathways, as determined primarily by immunohistochemistry and ultrastructure, can vary from indeterminate to myoid and/or neural. Recent work has indicated that the interstitial cells of Cajal, a complex cellular network postulated to act as pacemaker cells of the gastrointestinal tract, which exhibit both myoid and neural features, could be candidates for tumour histogenesis. This would provide a plausible and attractive explanation for the variable differentiation pathways identified in the GIST category to date. Nevertheless, the occasional but undisputed location of GISTs outside the gastrointestinal tract (omentum, peritoneum, and retroperitoneum) might mitigate against such an origin, and their histogenesis remains open to debate. The c-kit proto-oncogene, encoding a growth factor receptor with tyrosine kinase activity, has been postulated to play an important role in tumorigenesis because "gain of function" mutations in this gene, localised to chromosome 4q11-21, are being increasingly identified in hereditary and sporadic cases. Monoclonal and polyclonal antibodies directed at the c-kit gene product expressed on the cell surface (CD117/c-kit) appear to be increasingly helpful in resolving the histopathological differential diagnosis between GISTs and true gastrointestinal smooth muscle neoplasms, schwannomas, and other far less frequently occurring mesenchymal tumours at this site. Although tumours with a clinically benign course appear to be more common than their malignant counterparts, no specific histological criteria have as yet been identified to enable an unambiguous prediction of biological behaviour. Increasing tumour size and mitotic activity favour aggressive tumour behaviour, whereas the prognostic value of germline and somatic mutations within the c-kit proto-oncogene remains to be elucidated further. It is the aim of this synopsis to highlight the relevant fundamental and diagnostic developments with respect to this complex group of neoplasms.  (+info)

What we could do now: molecular pathology of gynaecological cancer. (8/85)

Gynaecological tumours exemplify many of the molecular paradigms of carcinogenesis. The clinical value of many of the molecular abnormalities present is now being tested and it is likely that the identification of at least some of these will become routine in the near future. This may help to refine diagnosis and guide treatment-for example, therapeutic vaccination for human papillomavirus related disease.  (+info)

Mesenchymoma is a very rare type of tumor that contains a mixture of different types of mesenchymal tissues, such as muscle, fat, bone, cartilage, or fibrous tissue. It typically occurs in children and young adults, and can be found in various parts of the body, including the head, neck, retroperitoneum (the area behind the abdominal cavity), and the limbs.

Mesenchymomas are usually slow-growing and may not cause any symptoms until they reach a large size. Treatment typically involves surgical removal of the tumor, but radiation therapy or chemotherapy may also be used in some cases. The prognosis for mesenchymoma depends on several factors, including the location and size of the tumor, the patient's age and overall health, and the specific types of tissue that are present in the tumor.

... (FCMB) is an extremely rare tumor first described in 1984. About 26 cases have been ... November 2011). "Fibrocartilaginous mesenchymoma, a unique osseous lesion: case report with review of the literature". Skeletal ... July 2017). "Fibrocartilaginous mesenchymoma of bone: a single-institution experience with molecular investigations and a ... Cherradi N, Jelthi A, Alhamany Z, Miri A, Forest M (1999). "[Fibrocartilaginous mesenchymoma of bone. A case report]". Clinical ...
4. Naka M, Matsumoto S, Shirai T, Itoh T (1975) Ganglioneuroblastoma associated with malignant mesenchymoma. Cancer 36:1050- ...
... mesenchymoma MeSH C04.557.435.525 - mixed tumor, malignant MeSH C04.557.435.530 - mixed tumor, mesodermal MeSH C04.557.435.540 ...
... histiocytoma of bone/osteosarcoma Osteosarcoma Rhabdomyosarcoma Leiomyosarcoma Myxosarcoma Fibrocartilaginous mesenchymoma of ...
... benign M8990/1 Mesenchymoma, NOS Mixed mesenchymal tumor M8990/3 Mesenchymoma, malignant Mixed mesenchymal sarcoma M8991/3 ...
... mesenchymoma, and spindle cell tumor. Soft tissue sarcomas are often detected as a firm mass located on the trunk, limbs, or ...
Fibrocartilaginous mesenchymoma of bone (FCMB) is an extremely rare tumor first described in 1984. About 26 cases have been ... November 2011). "Fibrocartilaginous mesenchymoma, a unique osseous lesion: case report with review of the literature". Skeletal ... July 2017). "Fibrocartilaginous mesenchymoma of bone: a single-institution experience with molecular investigations and a ... Cherradi N, Jelthi A, Alhamany Z, Miri A, Forest M (1999). "[Fibrocartilaginous mesenchymoma of bone. A case report]". Clinical ...
Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog. J Am Anim Hosp Assoc. 1998 Jul-Aug;34(4): ... Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog.. Publications // Richard Dubielzig // Jul ... A case of a malignant mesenchymoma with an unusual, vasoinvasive, metastatic behavior in a three-year-old, intact female basset ... No previous reports of a malignant mesenchymoma with vasoinvasive metastasis in the dog were found in the literature. The ...
... malignant mesenchymoma; alveolar soft-part sarcoma; epithelioid sarcoma; clear cell sarcoma; desmoplastic small cell tumor..." ...
Malignant Mesenchymoma * Malignant Peripheral Nerve Sheath Tumor * Malignant Primitive Neuroectodermal Tumor (PNET) ...
Mesenchymoma of the lung (so called hamartoma): a review of 154 parenchymal and endobronchial cases. van den Bosch JM, Wagenaar ...
Except for the mesenchymoma all tumours are commnon findings in the strain of rats used. The mesenchymoma found in a male top- ... one mesenchymoma in the skin and two fibroznatous polyps in the uterus. ...
Mesenchymoma (morphologic abnormality). Code System Preferred Concept Name. Mesenchymoma (morphologic abnormality). Concept ...
Malignant Mesenchymoma Whats New Last Posted: Jan 01, 2011 * Malignant mesenchymoma From NCATS Genetic and Rare Diseases ...
A knowledge graph of biological entities such as genes, gene functions, diseases, phenotypes and chemicals. Embeddings are generated with Walking RDF and OWL method ...
A knowledge graph of biological entities such as genes, gene functions, diseases, phenotypes and chemicals. Embeddings are generated with Walking RDF and OWL method ...
Mesenchymoma (benign) Page: Mesenchymoma (malignant) Page: Metaphyseal and metaphyseal-diaphyseal bone lesions Page: Metastasis ...
3 cases of mesenchymoma. - 6 cases of gastritis - 3 cases of normal stomach tissue. ...
Primary malignant mesenchymoma of bone Errol U. Hutagalung, Saukani Gumay, Bambang Budiatmoko, Suga Anggawidjaja ...
Benign mesenchymoma is a rare tumor composed of mature fat, thin small and medium-sized vessels and spindle cells of smooth ... Benign retroperitoneal mesenchymoma of childhood. JK Mahajan, Sunita Ojha, Kim Vaiphei, KLN Rao. July-September 2007, 12(3):138 ...
Malignant mesenchymal tumor 0 *Liver Neoplasms *Mesenchymoma. Intrahepatic ... Liver Neoplasms *Cholangiocarcinoma. CRG-. L2 ...
Malignant Mesenchymoma, Malignant Schwannoma (Malignant Peripheral Nerve Sheath Tumor). *Non-Bone Osterosarcoma ...
Computed tomography of a benign mesenchymoma of soft tissue. abstract::Computed tomography of a benign mesenchymoma in a 7-year ...
3. Fibrocartilaginous mesenchymoma with an unusual location in the rib. Page:75-78. ...
Medical definition and related topics for words beginning with M.
Chondrolipoma is a rare benign mesenchymoma composed of mature cartilage and adipose tissue. We present a 71-year-old man with ...
Herein, we present the fifth case of malignant mesenchymoma of the urinary bladder to be reported in the literature, which ... A case of malignant mesenchymoma of the bladder containing leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, osteosarcoma, and ... In summary, malignant mesenchymoma is a rare tumor, and this is the fifth reported case of a malignant mesenchymoma of the ... Table 1 Immunohistochemical results for all kinds differentiated components of malignant mesenchymoma. Full size table. ...
Mesenchymoma [C04.557.435.500] * Mixed Tumor, Malignant [C04.557.435.525] * Mixed Tumor, Mesodermal [C04.557.435.530] ...
Generally, when equally divided, a tumor consisting of more than one type of mesenchymal tissue is called a mesenchymoma. The ...
Primary Left Atrial Malignant Mesenchymoma:A Case Report:原發性左心房惡性間葉瘤:一例報告 ...
Malignant mesenchymoma is a rare type of sarcoma that shows features of fibrosarcoma and features of at least 2 other types of ...
... another superbug bullrushes daringly espouse underneath one semipsychological mesenchymoma. In addition to hematotropic ...
... with rhabdomyosarcomatous differentiation in local recurrence and lung metastases or so-called malignant mesenchymoma of soft ...
... and mesenchymoma of connective tissue (Sa19). It is proven that great activity of glucose and weak respiration of the OV cells ...
  • A case of malignant mesenchymoma of the bladder containing leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, osteosarcoma, and myxomatous components is described. (biomedcentral.com)
  • Fibrocartilaginous mesenchymoma of bone (FCMB) is an extremely rare tumor first described in 1984. (wikipedia.org)
  • Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog. (wisc.edu)
  • A case of a malignant mesenchymoma with an unusual, vasoinvasive, metastatic behavior in a three-year-old, intact female basset hound is presented. (wisc.edu)
  • There were exams on three types of respiration of human's cancerous cells and ultra-structures: specifically, ovarian cancer (OV), stomach cancer (CaVe) and mesenchymoma of connective tissue (Sa 19 ). (medicalamber.com)
  • 1. Surgical case of giant malignant mesenchymoma in the posterior mediastinum that recurred in the bilateral mediastinum. (nih.gov)
  • 15. [Malignant mesenchymoma of the retroperitoneum: a case report]. (nih.gov)
  • 17. [Recurrent pericarditis revealing a malignant mediastinal mesenchymoma]. (nih.gov)
  • Malignant mesenchymoma. (indiasurgerytour.com)
  • n\nMixed malignant mesenchymoma. (clinconnect.io)
  • 3. Benign mesenchymoma of the mediastinum. (nih.gov)
  • 5. Giant benign mesenchymoma of the mediastinum causing superior vena cava syndrome: report of a case. (nih.gov)
  • 8. Benign mesenchymoma of the mediastinum. (nih.gov)
  • Benign mesenchymoma of the stomach. (bmj.com)
  • Fibrocartilaginous mesenchymoma of bone (FCMB) is an extremely rare tumor first described in 1984. (wikipedia.org)
  • Fibrocartilaginous mesenchymoma: a clinicopathological analysis of four cases]. (bvsalud.org)
  • To investigate the clinical, radiological, histological and molecular features and the differential diagnosis of fibrocartilaginous mesenchymoma (FM). (bvsalud.org)
  • The term mesenchymoma was originally defined by Stout in 1948 to describe tumors containing at least two mesenchymal tissues not normally found together [1]. (jocr.co.in)